公开(公告)号：US20210299114A1

公开(公告)日：2021-09-30

申请号：US17199896

申请日：2021-03-12

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

Inventor： Ram H. Nagaraj ,  Rooban B. Nahomi ,  Mi-hyun Nam

IPC: A61K31/47 ,  A61K9/00 ,  A61P3/10 ,  A61P27/06

Abstract: Methods of treating, reducing the risk of, preventing, or alleviating at least one symptom of a retinal disease, injury, or condition in a subject involve administering a pharmaceutically effective amount of kynurenic acid to the subject. The kynurenic acid may be administered intravenously or intravitreally. Systems for treating retinal diseases, injuries, or conditions are also disclosed and may include an administration device.

公开(公告)号：US20240115538A1

公开(公告)日：2024-04-11

申请号：US18193910

申请日：2023-03-31

Applicant: The Regents of the University of Colorado, a Body Corporate

Inventor： Ram H. Nagaraj ,  Rooban B. Nahomi ,  Sandip Nandi

IPC: A61K31/223 ,  A61K31/265 ,  A61P27/10

CPC classification number: A61K31/223 ,  A61K31/265 ,  A61P27/10

Abstract: Methods of treating, preventing, delaying, or reversing presbyopia in a subject involve administering a pharmaceutically effective amount of an aggrelyte to the subject. The aggrelyte may be one or more of N,S-diacetyl-L-cysteine methyl ester, S-acetyl-N-(3,3,-dimethylbutanoyl)-L-cysteinate, or N-acetyl cysteine methyl ester. The aggrelyte may be administered topically.